Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen

Cancer Immunology Immunotherapy

Volumn 49, Issue 6, 2000, Pages 285-295

  Mizobata, Shizuma ^a   Tompkins, Kevin ^b   Simpson, Jean F ^b   Shyr, Yu ^c   Primus, F James ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive therapy; Carcinoembryonic antigen; Cytotoxic T cell; Tolerance; Transgenic mice

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CROSS REACTING ANTIGEN; CYCLOPHOSPHAMIDE; EPITOPE; GLYCOPROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TRANSGENIC MOUSE;

EID: 0033854943     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000116     Document Type: Article

References (51)

1. T cell tolerance and activation to a transgene-encoded tumor antigen
2. Tumor antigens recognized by T lymphocytes
3. Identification of cytotoxic T cell epitopes for epithelial tumors by in vitro immunization of lymphocytes with peptide-pulsed dendritic cells
4. Therapy with cultured T cells: Principles revisited
5. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues
6. Mice transgenic for carcinoembryonic antigen as a model for immunotherapy
7. Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus vaccine in man
8. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure
9. Transcription of genes of the carcinoembryonic antigen family in malignant and non-malignant human tissues
10. Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV40 large T antigen
11. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern
12. Prognostic relevance of carcinoembryonic antigen and estrogen receptor in breast cancer patients
13. Allele-specific motifs revealed by sequencing of self-peptidese eluted from MHC molecules
14. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine
15. Phase I study of recombinant vaccinia virus (rv) that express human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas
16. Human tumor antigens are ready to fly
17. Immunoglobulins reactive to carcinoembryonic antigen and their relationship to the antigen in malignant ascitic fluid of ovarian carcinoma
18. Cancer antigens: Immune recognition of self and altered self
19. 2
20. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus
21. T cell anergy
22. Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens
23. T-cell tolerance
24. Absence of circulating antibodies to carcinoembryonic antigen in patients with gastrointestinal malignancies
25. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
26. Lack of correlation between carcinoembryonic antigen content of tumor extracts and leukocyte migration reactivity of tumor patients
27. Antitumor activity of corynebacterium parvum
28. T-cell tolerance and autoimmunity in transgenic models of central and peripheral tolerance
29. Self-ignorance in the peripheral T-cell pool
30. T-cell-mediated immunity to carcinoembryonic antigen in humans: An example of 'swimming upstream'?
31. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
32. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
33. Sensitization of human lymphocytes to carcinoembryonic antigen (CEA): Neutralization experiments with anti-CEA sera
34. Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen
35. Negative selection of lymphocytes
36. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice
37. Carcinoembryonic antigen (CEA) deduced from cDNA sequence
38. Tumor immunity as autoimmunity: Tumor antigens include normal self proteins which stimulate anergic peripheral T cells
39. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels
40. Localization of human GW-39 tumors in hamsters by radio-labeled heterospecific antibody to carcinoembryonic antigen
41. Self-reactive antibody expression by human colon carcinoma cells engineered with monoclonal antibody genes
42. Human CTL epitopes encoded by human papillomavirus type E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides
43. Immunologic approaches to diagnosis of malignancy
44. Targeting p53 as a general tumor antigen
45. Molecular cloning and expression of carcinoembryonic antigen gene family members
46. The carcinoembryonic antigen gene family: Structure, expression and evolution
47. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
48. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy
49. The immunoglobulin super-family: Domains for cell recognition
50. 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial
51. Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tumors